Amendment: SEC Form SC 13G/A filed by Atossa Therapeutics Inc.

11/4/24 11:27:58 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ATOS alert in real time by email

SC 13G/A 1 UnitedStates_13G__AtossaTher.txt 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. )* (Name of Issuer) Atossa Therapeutics Inc (Title of Class of Securities) Common Stock (CUSIP Number) 04962H506 (Date of Event Which Requires Filing of this Statement) September 30, 2024 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: X Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, an* d for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of * the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 04962H506 (1) Names of reporting persons The Vanguard Group (2) Check the appropriate box if a member of a group (a) (see instructions) (b) X (3) SEC use only (4) Citizenship or place of organization Pennsylvania Number of shares beneficially owned by each reporting person with: (5) Sole voting power 0 (6) Shared voting power 82,445 (7) Sole dispositive power 6,469,502 (8) Shared dispositive power 128,794 (9) Aggregate amount beneficially owned by each reporting person 6,598,296 (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions) (11) Percent of class represented by amount in Row (9) 5.24% (12) Type of reporting person (see instructions) IA Item 1(a) Name of issuer: Atossa Therapeutics Inc Item 1(b) Address of issuer's principal executive offices: 10202 5th Avenue North East, Suite 200 Seattle, WA 98125 Items 2(a)-2(c). Name, Address Of principal business office, and Citizenship of* persons filing: The Vanguard Group - 23-1945930 100 Vanguard Blvd. Malvern, PA 19355 2(d) Title of class of securities: Common Stock 2(e) CUSIP Number: 04962H506 Item 3. This statement is being filed pursuant to Rule 13d-1. An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E). Item 4. Ownership As of the close of business on September 30, 2024: (a) Aggregate amount beneficially owned: 6,598,296 (b) Percent of class: 5.24% (c) Number of shares as to which person has: 1. The Vanguard Group (a) Amount beneficially owned: 6,598,296 (b) Percent of class: 5.24% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 82,445 (iii) Sole power to dispose or to direct the disposition of: 6,469,502 (iv) Shared power to dispose or to direct the disposition of: 128,794 Item 5.Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following . Item 6. Ownership of More than 5 Percent on Behalf of Another Person. The Vanguard Group, Inc.'s clients, including investment companies registered u* nder the Investment Company Act of 1940 and other managed accounts, have the ri* ght to receive or the power to direct the receipt of dividends from, or the pro* ceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5* %. Item 7. Identification and Classification of the Subsidiary Which Acquired the

Get the next $ATOS alert in real time by email

Amendment: SEC Form SC 13G/A filed by Atossa Therapeutics Inc.

11/4/24 11:27:58 AM ET

$ATOS

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ATOS alert in real time by email

Amendment: SEC Form SC 13G/A filed by Atossa Therapeutics Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$ATOS

Amendment: SEC Form SC 13G/A filed by Atossa Therapeutics Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$ATOS

$ATOS
SEC Filings

Atossa Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

Atossa Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

SEC Form DEF 14A filed by Atossa Therapeutics Inc.

$ATOS
Press Releases

Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer

Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category

Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium

$ATOS
Insider Purchases

President & CEO Quay Steven C bought $9,887 worth of shares (11,239 units at $0.88), increasing direct ownership by 423% to 13,898 units (SEC Form 4)

Director Remmel H. Lawrence bought $7,000 worth of shares (10,000 units at $0.70), increasing direct ownership by 3,891% to 10,257 units (SEC Form 4)

Finn Jonathan bought $44,250 worth of shares (25,000 units at $1.77) (SEC Form 4)

$ATOS
Insider Trading

SEC Form 4 filed by Chief Financial Officer Daniel Mark James

SEC Form 3 filed by new insider Daniel Mark James

President & CEO Quay Steven C bought $9,887 worth of shares (11,239 units at $0.88), increasing direct ownership by 423% to 13,898 units (SEC Form 4)

$ATOS
Leadership Updates

Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness

Atossa Therapeutics Names Janet R. Rea, MSPH, as Senior Vice President, R&D to Accelerate (Z)-Endoxifen Toward Key Regulatory Milestones

Atossa Therapeutics Appoints CORE IR for Investor Relations, Shareholder Communications and Public Relations Services

$ATOS
Large Ownership Changes